



March 12, 2018

Dear Wholesaler:

As a valued health care provider and partner, we want to share with you that Orexigen Therapeutics, Inc. has announced the decision to sell all of the assets of the company by the end of June using a structured process through Chapter 11 of the U.S. Bankruptcy Code. In light of this decision, we wanted to take this opportunity to reassure you that we remain committed as ever to serving patients. This will not affect your ability to order and distribute Contrave[®] (naltrexone HCl and bupropion HCl extended release) or for your customers and their patients to start and stay on CONTRAVE. Orexigen's normal day-to-day operations will continue without interruption.

Orexigen was founded on the premise of helping to improve the health and lives of patients struggling to lose weight, and we remain as committed as ever to that mission. CONTRAVE is the #1 prescribed weight loss brand and almost 800,000 patients have benefitted from CONTRAVE since launch¹, but we also know that many more patients could benefit. Through this near-term sale, along with our continued, active promotion, and support from providers such as yourself, we confidently intend to serve the growing patient demand.

Below are answers to some questions you may have.

1. Will there be any disruption of the availability of CONTRAVE at the pharmacy?
 - a. No, CONTRAVE will continue to be available at the pharmacy.
2. Who should I contact if I have any questions?
 - a. Your primary point of contact will remain Brian Longstreet at Orexigen. His phone number is 908-917-5699 and email address is blongstreet@orexigen.com.

Here are links to both of our websites:

www.contrave.com (for patients)

www.contravehcp.com (for providers)

The Company has filed a motion in the U.S. Bankruptcy Court seeking authority to honor certain pre-petition obligations and to continue customer programs. Additionally, the Company has received a \$35M financing commitment, subject to court approval, which provides the company with sufficient liquidity to conduct its business in an uninterrupted manner and continue to meet its operational and financial obligations, including continued servicing of distributors, wholesalers and global partners to ensure timely fulfillment of orders and shipments of CONTRAVE. These funds will satisfy customary obligations

associated with ongoing operations of the Company's business, including payment of post-petition obligations to you under existing terms. The First Day Motions and related bankruptcy filings can be seen on the public website at www.kccllc.net/orexigen.

CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m² or greater (obese), or adults with a BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.

One of the ingredients in CONTRAVE, bupropion, may increase the risk of suicidal thinking in children, adolescents, and young adults. CONTRAVE patients should be monitored for suicidal thoughts and behaviors. In patients taking bupropion for smoking cessation, serious neuropsychiatric adverse events have been reported. CONTRAVE is not approved for use in children under the age of 18.

Thank you for all you have done to support us up until now and thank you in advance for your ongoing support as we transition through this process.

Very truly yours,

A handwritten signature in black ink, appearing to read "Michael Narachi". The signature is fluid and cursive, with the first name being more prominent.

Michael Narachi
President & Chief Executive Officer